The rise of immune checkpoint inhibitor immunotherapy in cancer has brought an array of immune-related adverse events (irAEs) with it. Many of these are within the domain of the rheumatologist, including inflammatory arthritis, sicca symptoms, polymyalgia rheumatica-like disease, and myositis. Despite this escalating disease burden, very little is yet known about the exact nature of rheumatic irAE clinical phenotypes or their relevance to management. Furthermore, given that some of this provoked inflammatory disease bears resemblence to classical idiopathic autoimmune rheumatic diseases, the study of irAEs may provide 'bedside-to-bench' insights about the pathogenesis of classical idiopathic disease.
This talk will briefly address the latest in what is known about rheumatic irAE phenotypes, and discuss avenues for further exploration.